Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle

Página do item simplificado
dc.contributor.authorCubero, Daniel I. G.
dc.contributor.authorCruz, Felipe Melo
dc.contributor.authorSanti, Patricia
dc.contributor.authorSilva, Ismael Dale C. G. [UNIFESP]
dc.contributor.authordel Giglio, Auro
dc.contributor.institutionABC Fdn Sch Med
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionAlbert Einstein Jewish Hosp
dc.date.accessioned2016-01-24T14:27:27Z
dc.date.available2016-01-24T14:27:27Z
dc.date.issued2012-07-01
dc.description.abstractObjective: the objective of this study was to evaluate the safety of using tegafur-uracil (UFT) in colorectal cancer patients with partial dihydropyrimidine dehydrogenase (DPD) deficiency.Patients and Methods: the study included five colorectal cancer patients who presented with acute toxicity (grades 3 and 4) after being given the first cycle of chemotherapy using 5-fluorouracil. the DPD deficiency was confirmed by gene sequencing. After a full recovery from all side effects, we changed the regimen to UFT (300 mg/m(2)/day) associated with leucovorin (90 mg/day) for 21 days, with an empirical dose reduction of at least 10% in the first cycle.Results: We prospectively analysed 22 UFT cycles in 5 patients. We did not observe any episodes of grade 3 or 4 toxicity. the predominant toxicities were of grades 1 and 2 (nausea, vomiting and diarrhoea).Conclusion: Here, we demonstrate a complete absence of severe toxicity in all patients and cycles analysed. We believe that UFT is a safe alternative for the treatment of patients with partial DPD deficiency.en
dc.description.affiliationABC Fdn Sch Med, Dept Haematol & Oncol, BR-09060650 Santo Andre, SP, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, UNIFESP, São Paulo Sch Med, Dept Gynaecol, São Paulo, Brazil
dc.description.affiliationAlbert Einstein Jewish Hosp, Med Coordinator Oncol Sect, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, UNIFESP, São Paulo Sch Med, Dept Gynaecol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent167-172
dc.identifierhttp://dx.doi.org/10.1177/1758834012441049
dc.identifier.citationTherapeutic Advances in Medical Oncology. London: Sage Publications Ltd, v. 4, n. 4, p. 167-172, 2012.
dc.identifier.doi10.1177/1758834012441049
dc.identifier.issn1758-8340
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/35081
dc.identifier.wosWOS:000208965400002
dc.language.isoeng
dc.publisherSage Publications Ltd
dc.relation.ispartofTherapeutic Advances in Medical Oncology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.uk.sagepub.com/aboutus/openaccess.htm
dc.subjectcolorectal neoplasmsen
dc.subjectdihydropyrimidine dehydrogenase deficiencyen
dc.subjectdrug toxicityen
dc.subjectfluorouracilen
dc.subjecttegafuren
dc.subjecturacilen
dc.titleTegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principleen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos